Navigation Links
Long-Term Soliris(R) Therapy Improved or Stabilized Kidney Function in Patients With PNH
Date:12/10/2007

Study Shows that Long-Term Soliris Therapy Continued to Be Associated with Reductions in Thrombosis and Improvements in Fatigue, Quality of Life, and

Anemia in PNH Patients Data Presented at the American Society of Hematology (ASH) Annual Meeting

Posters: 897-III & 891-III

CHESHIRE, Conn., Dec. 10 /PRNewswire-FirstCall/ -- Patients with a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH) were found to be six times more likely than the general public to have chronic kidney disease (CKD), as shown in an ongoing open-label clinical study of patients with PNH. Additionally, results from clinical studies in patients with PNH presented today at the American Society of Hematology (ASH) Meeting in Atlanta indicated that long-term treatment with Soliris(R) (eculizumab) was associated with significant improvement and stabilization of kidney function. In a separate presentation of results from the same clinical studies, the long-term reduction in hemolysis with Soliris therapy was associated with sustained reduction in thrombosis and improvements in fatigue, overall quality of life, as well as anemia as measured by reductions in transfusions in a diverse population of patients with PNH. Soliris continued to be safe and well- tolerated throughout this open-label study.

The data were presented in two poster presentations titled, "High Incidence of Progression to Chronic Renal Insufficiency in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)" and "Sustained Improvements in Transfusion Requirements, Fatigue and Thrombosis with Eculizumab Treatment in Paroxysmal Nocturnal Hemoglobinuria."

Soliris, Hemolysis and PNH

Soliris, developed by Alexion Pharmaceuticals, Inc. (Nasdaq:

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
6. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015  Relmada Therapeutics, ... therapies for the treatment of chronic pain, today ... researchers to advisory roles. The panel of experts ... programs and efforts to advance the company pipeline ... They bring expertise in a range of areas ...
(Date:3/5/2015)... 5, 2015 - Cross reference: ... http://www.epa.eu ) - Hitachi Medical Systems ... generazione di OASIS* all,ECR 2015. Si tratta di un ... da 1.2 T che migliora la capacità diagnostica dei ... al comfort del paziente. Le nuove funzionalità di OASIS ...
(Date:3/5/2015)... HAMPTON, N.J. , March 5, 2015 ... a leading global specialty biopharmaceutical company, and Ikaria, Inc. ... have entered into a definitive agreement under which a ... Madison Dearborn -led investor group in a transaction ... to customary closing conditions, the parties expect the transaction ...
Breaking Medicine Technology:Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 2Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 4Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 2Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 3Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 4Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 2Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 3Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 4Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 5Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 6Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 7Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 8Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 9
... III pivotal trial demonstrate safety and,efficacy of first ... severe COPD --, NAPA, Calif., May 16, 2007 ... presentations will be given at the,International Conference of ... at the Moscone Center in San Francisco. The,presentations ...
... WIRE)--May 17, 2007 - Results,published this week in ... (Quadrivalent Human Papillomavirus (Types 6, 11,16, 18) Recombinant ... and vaginal dysplasias caused by HPV,types 16 and ... 100 percent protection was observed in women who ...
Cached Medicine Technology:Clinical Trial Data for Perforomist Inhalation Solution to be,Presented at ATS on May 20, 2007 2Clinical Trial Data for Perforomist Inhalation Solution to be,Presented at ATS on May 20, 2007 3Clinical Trial Data for Perforomist Inhalation Solution to be,Presented at ATS on May 20, 2007 4Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 2Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 3Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 4Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 5Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 6Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 7Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 8Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 9Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 10Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 11Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 12Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 13Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 14Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 15Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 16Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 17Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 18Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 19Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 20Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 21Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 22Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 23Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 24Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 25Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 26Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 27Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 28Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 29Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 30Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 31Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 32
(Date:3/5/2015)... Rosa, CA (PRWEB) March 05, 2015 SuperCloset ... a SuperPro! The series aims to teach viewers everything ... garden with hydroponics. Grow Like a SuperPro takes you from ... between. From how to clone, to how to prune Grow ... growing. They are offering the whole series for download for ...
(Date:3/5/2015)... HMP Communications Holdings , ... education, announced today its acquisition of the ... medical conference designed for health care providers dedicated ... amputation due to vascular disorders. The 5-year-old ... publications and CME activities across therapeutic fields such ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Taking ... in Fort Worth, Texas April 9-11th is IDRevolution ... company providing personalized nutrition. IDLife offers a ... IDNutrition. This customized approach to vitamin supplementation ... begins with a free HIPAA compliant online assessment ...
(Date:3/5/2015)... Minneapolis, Minn. (PRWEB) March 05, 2015 ... authority, invites healthcare organizations to participate in its ... includes data from executive and director-level positions, and ... , Last year’s report featured data on ... 28 independent children’s healthcare organizations and 7 subsidiary ...
(Date:3/5/2015)... 05, 2015 Nutrition Leaders, a premier ... pleased to offer reformulated Millennium 500 Creatine to its ... is a German grade creatine supplement that has been ... recovery, and aid with overall strength gains in users. ... as a reserve energy source in the body and ...
Breaking Medicine News(10 mins):Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 3Health News:IDLife Partners John C. Maxwell and Troy Aikman speaking at IDRevolution in Fort Worth, TX April 9th-11th, 2015 2Health News:Participation Is Now Open For INTEGRATED Healthcare Strategies 2015 Children’s Hospitals Executive Compensation Survey 2Health News:Nutrition Leaders Offers Reformulated Millennium 500 German Grade Creatine 2
... viruses due to their protective protein cover which protects them. ... //. ,Tackling this problem, scientists at the Institut ... the European Molecular Biology Laboratory (EMBL) in Grenoble have found ... a protein that allows the rabies virus to be harmful ...
... Australian beauty with roots in India open to acting in ... in India// who will represent Australia in the Miss World ... ,The first person of non-Australian parentage to win the ... an Indian mother and a Lebanese father. ,Sabrina, ...
... of Union Health Minister Anbumani Ramdoss, a pro-reservation ... P Venugopal and some senior doctors for allegedly ... Delhi against reservations for OBCs in higher education. ... members of the institution instigated the anti-quota protests ...
... According to a finding published in the medical journal Pediatrics, ... to guard// against chicken pox spurt in schools. ,Dr. ... Health conducted a study during an outbreak of chicken pox ... the 545 children attending the school had not suffered chicken ...
... in place of regular salt in everyday diet could ... , high blood pressure and diabetes, a study has ... Institutes in Taiwan and fellow researchers studied nearly 2,000 ... ,The researchers asked cooks at the retirement home to ...
... Swaraj today expressed concern over the turf war between Union ... saying it could "destroy the premier institution". ,"I am ... institution is being destroyed by the present union minister," she ... are working there and it is churning out the best ...
Cached Medicine News:
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... Many special order products are offered as ... long lengths. The modular instruments may be ... options such as ratchets, insulation and flush ... Mediflex stock. Customer specifications may affect delivery ...
Medicine Products: